Vivolux applies the solid scientific competence found in the company network to the development of new and innovative applications for use in cancer therapy. Our research and development projects are supported by advanced culture systems for drug screening and lead optimization.
The assessment and development of the optimal approach to external leads is a collaborative process between the company and its partners. Once in the clinical phase the projects are executed in collaboration with leading US cancer institutions.
Our vision is to use our creativity to develop new mechanisms of action and substances that will serve as lifesaving tools, in the treatment of cancer. By continually striving to increase our knowledge of medicinal chemistry and biological systems we are becoming more expert in finding future solutions to current medical issues.
Vivolux was founded in Sweden in 2004 with a focus on the development of novel cancer drugs based on phenotypic models, where the unique behavior of malignant cells under specific conditions is utilized to identify new targets and molecules acting on these targets. Working in close collaboration with research groups at Uppsala University and the Karolinska Institute, Vivolux has developed a unique and comprehensive system for preclinical analysis of cancer drugs, including tests on primary cultures of human cancer cells, cells grown in three-dimensional aggregates and methods for molecular investigation of mechanism of action. Several drug candidates have been identified and optimized and the results from these investigations have been published in international scientific journals. Two novel drugs with new mechanisms of action for cancer treatment are currently undergoing in clinical investigation in collaboration with leading cancer institutes in the USA.